Reseach programme: integrin inhibitors - Aviara Pharmaceuticals

Drug Profile

Reseach programme: integrin inhibitors - Aviara Pharmaceuticals

Alternative Names: AVA 3486; α4β7 integrin inhibitor - Aviara Pharmaceuticals

Latest Information Update: 19 Jan 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Aviara Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Alpha4-beta7 integrin antagonists; Integrin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Dry eyes; Inflammatory bowel diseases
  • Research Cancer

Most Recent Events

  • 17 Jan 2017 Early research in Cancer in USA (unspecified route)
  • 17 Jan 2017 Preclinical trials in Dry eyes in USA (Topical)
  • 17 Jan 2017 Preclinical trials in Inflammatory bowel disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top